The accumulation of Tc-99m in knee and finger joints was studied in 41 rheumatic patients and 25 controls. The accumulation of the radioisotope was correlated with the intensity of active inflammation. Rheumatoid joints showed a stronger Tc-99m uptake than joints with osteoarthritis. There was some overlap, however, which limits the value of the method. The effect of local and systemic anti-rheumatic treatments could be followed with joint scanning. Radioactivity was also measured in the synovial fluid but this fraction of the Tc-99m was not large. The synovial fluid radioactivity tended to increase as the Tc-99m accumulation in the knee area decreased. Accumulation of Tc-99m in joints is regarded as principally due to the enhanced circulation in inflamed joint tissues.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/03009747009165380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Tc]Technetium and Rhenium Dithiocarbazate Complexes: Chemical Synthesis and Biological Assessment.
Pharmaceutics
January 2025
Laboratory of Nuclear Medicine (LIM-43), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo 05403-911, SP, Brazil.
Background/objectives: Dithiocarbazates (DTCs) and their metal complexes have been studied regarding their property as anticancer activities. In this work, using S-benzyl-5-hydroxy-3-methyl-5-phenyl-4,5-dihydro-1H-pirazol-1-carbodithionate (Hbdtc), we prepared [ReO(bdtc)(Hbdtc)] and [[Tc]TcO(bdtc)(Hbdtc)] complexes for tumor uptake and animal biodistribution studies.
Methods: Re complex was prepared by a reaction of H2bdtc and (NBu)[ReOCl], the final product was characterized by IR, H NMR, CHN, and MS-ESI.
Evaluation of maSSS/maSES-PEG2-RM26 for their potential therapeutic use after labeling with Re-188. Could their [Tc]Tc-labeled counterparts be used to estimate dosimetry?
EJNMMI Radiopharm Chem
January 2025
Department of Medicinal Chemistry, Uppsala University, Uppsala, 751 23, Sweden.
Background: Gastrin releasing peptide receptor (GRPR)-directed radiopharmaceuticals for targeted radionuclide therapy may be a very promising addition in prostate and breast cancer patient management. Aiming to provide a GRPR-targeting theranostic pair, we have utilized the Tc-99m/Re-188 radiometal pair, in combination with two bombesin based antagonists, maSSS-PEG2-RM26 and maSES-PEG2-RM26. The two main aims of the current study were (i) to elucidate the influence of the radiometal-exchange on the biodistribution profile of the two peptides and (ii) to evaluate the feasibility of using the [Tc]Tc labeled counterparts for the dosimetry estimation for the [Re]Re-labeled conjugates.
View Article and Find Full Text PDFNoninvasive Imaging of Immune Cell Activity in Myocardial Infarction Phases Using Tc-HYNIC-mAb SPECT/CT.
Mol Pharm
January 2025
Department of Geriatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Acute myocardial infarction (MI) remains a leading cause of mortality worldwide, with inflammatory and reparative phases playing critical roles in disease progression. Currently, there is a pressing need for imaging techniques to monitor immune cell infiltration and inflammation activity during these phases. We developed a novel probe, Tc-HYNIC-mAb, utilizing a monoclonal antibody that targets the voltage-gated potassium channel 1.
View Article and Find Full Text PDFNovel Chlorin with a HYNIC: Synthesis, Tc-Radiolabeling, and Initial Preclinical Evaluation.
Molecules
December 2024
M. V. Lomonosov Institute of Fine Chemical Technology, MIREA-Russian Technological University, 86 Vernadsky Av., 119571 Moscow, Russia.
The use of radiopharmaceuticals for diagnostics in oncology allows for the detection of the disease at an early stage. Among diagnostic radionuclides, Tc is a promising isotope that has been used to create several drugs for clinical use. One of the most effective Tc chelators is 6-hydrazinylnicotinic acid (HYNIC), which, when combined with various vector molecules, can be used for targeted delivery of radionuclides to tumor tissues.
View Article and Find Full Text PDFLocalized In Vivo Prodrug Activation Using Radionuclides.
J Nucl Med
January 2025
Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts;
Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically activate prodrugs at disease sites while avoiding activation in off-target sites of toxicity. As proof of principle, we tested whether this strategy of radionuclide-induced drug engagement for release (RAiDER) could locally deliver combined radiation and chemotherapy to maximize tumor cytotoxicity while minimizing off-target exposure to activated chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!